The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

EHA 2019 | Novel therapies targeting the innate immune system in MDS

Name: Novel therapies targeting the innate immune system in MDS
Uploaded: 2019-06-15T14:01:18.000Z
Duration: 1 min 15 s
Description: Alan List, MD, from the Moffitt Cancer Center, Tampa, FL, talks about new therapies that have the potential to target the innate immune system in myelodysplastic syndromes (MDS). This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Alan List • 15 Jun 2019

EHA 2019

Myelodysplastic Syndromes Azacitidine Ibrutinib

Alan List, MD, from the Moffitt Cancer Center, Tampa, FL, talks about new therapies that have the potential to target the innate immune system in myelodysplastic syndromes (MDS). This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.